KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other financing activities (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Other financing activities readings, the most recent being $39.0 million for Q1 2026.

  • On a quarterly basis, Other financing activities fell 13.33% to $39.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $84.0 million, a 35.38% decrease, with the full-year FY2025 number at $90.0 million, down 53.85% from a year prior.
  • Other financing activities hit $39.0 million in Q1 2026 for Thermo Fisher Scientific, down from $91.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $110.0 million in Q1 2024 to a low of -$42.0 million in Q2 2025.
  • Median Other financing activities over the past 5 years was $20.0 million (2022), compared with a mean of $21.8 million.
  • Biggest five-year swings in Other financing activities: crashed 270.0% in 2022 and later soared 775.0% in 2024.
  • Thermo Fisher Scientific's Other financing activities stood at $20.0 million in 2022, then decreased by 30.0% to $14.0 million in 2023, then crashed by 221.43% to -$17.0 million in 2024, then skyrocketed by 635.29% to $91.0 million in 2025, then plummeted by 57.14% to $39.0 million in 2026.
  • The last three reported values for Other financing activities were $39.0 million (Q1 2026), $91.0 million (Q4 2025), and -$4.0 million (Q3 2025) per Business Quant data.